Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules.

ABSTRACT:

Objectives

Some drugs that augment cell-intrinsic defenses or modulate cell death/survival pathways have been reported to selectively kill cells infected with HIV or Simian Immunodeficiency Virus (SIV), but comparative studies are lacking. We hypothesized that these drugs may differ in their ability to kill cells infected with intact and defective proviruses.

Design

To investigate this hypothesis, drugs were tested ex vivo on peripheral blood mononuclear cells (PBMC) from nine antiretroviral therapy (ART)-suppressed individuals.

Methods

We tested drugs currently in clinical use or human trials, including auranofin (p53 modulator), interferon alpha2A, interferon gamma, acitretin (RIG-I inducer), GS-9620/vesatolimod (TLR7 agonist), nivolumab (PD-1 blocker), obatoclax (B

SUBMITTER: Kadiyala GN 

PROVIDER: S-EPMC11216394 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature